Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).
A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).
Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture.
JAMA Open Network reports that reducing four particular risk factors for gout could slash incident cases in men.
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR).
Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.
A tenet of drug management suggests that steroid use in psoriasis may be associated with rebound flares; well this has been challenged by a new observational trial showing that the risk of flares (and severe flares) of psoriasis flares were seldom triggered by systemic steroids - certainly much less than what is traditionally taught in dermatology
The SELECT-PsA 2 trial was presented at the ACR meeting and recently published in Annals of Rheumatic Disease, shows that psoriatic arthritis (PsA) patients who have failed at least one biologic DMARD, did respond well to upadacitinib.
Centers for Medicare & Medicaid's CY 2021 Medicare Physician Fee Schedule final rule provides much-needed increases in Medicare reimbursement for the evaluation and management (E/M) services provided by rheumatologists and other cognitive care specialties to Medicare beneficiaries.
Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.
The CDC advisory panel, ACIP, has voted and declared that the first wave of vaccines should go to the front line healthcare workers and elderly residents in long term care facilities as part of Phase1a. The decision was not unanimous.
Dr Jack Cush takes questions from RheumNow listeners
PIANO Study - Safety of Biologics in Pregnancy
Premature osteoporosis and high tryptase
Mega-methotrexate doses
SLE criteria and SLEDAI substitutions
The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.
